Indaptus Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a INDP research report →
Price Chart
About the company
Indaptus Therapeutics, Inc. is a biotechnology company operating in the pre-clinical phase, dedicated to developing a range of immunotherapeutic products for the treatment of both cancer and viral infections. The firm's lead investigational compound, Decoy20, is currently progressing through Phase I clinical trials.
- CEO
- Junyi Dai
- IPO
- 2015
- Employees
- 5
- HQ
- New York City, NY, US
Get TickerSpark's AI analysis on INDP
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $293.30M
- P/E
- -0.37
- Fwd P/E
- 3.28
- PEG
- -0.00
- P/S
- 0.00
- P/B
- 26.45
- EV/EBITDA
- -18.49
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -302.75%
- ROIC
- -129.90%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-19,833,513
- Net Income
- $-20,848,916-38.8%
- EPS
- $-21.58+52.0%
- OCF Growth
- -20.3%
- FCF Growth
- -20.3%
- 52W High
- $5.96
- 52W Low
- $0.92
- 50D MA
- $1.96
- 200D MA
- $2.27
- Beta
- 1.17
- RSI (14)
- 49
- Avg Volume
- 831.01K
No earnings-call transcripts are available for INDP yet.
- Free Float
- 3.6%
- Shares Outstanding
- 113.24M
- Float Shares
- 4.02M
of shares held by institutions
6 13F filers
Buy/sell ratio 1.20. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Hrt Financial LP | 206.08K | ▲ 206.08K |
| Geode Capital Management, LLC | 56.47K | ▲ 29.46K |
| Jane Street Group, LLC | 53.81K | ▲ 53.81K |
| Vanguard Capital Management LLC | 33.65K | ▲ 33.65K |
| Vanguard Fiduciary Trust Co | 13.97K | ▲ 13.97K |
| Millennium Management LLC | 11.59K | ▲ 11.59K |
| Morgan Stanley | 8.94K | ▲ 6.24K |
| Ubs Group AG | 478 | ▲ 478 |
| Sbi Securities Co., Ltd. | 17 | 0 |
| Cwm, LLC | 2 | ▲ 2 |
Held by 8 ETFs
Biggest fund positions in INDP by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Apr 8, 26 | Lu Qinglai | other | 0 |
| Mar 23, 26 | Yao Yun | other | 0 |
| Mar 23, 26 | SINO LION VENTURES Ltd | other | 0 |
| Mar 23, 26 | Dai Junyi | other | 0 |
| Mar 23, 26 | Lazar David E. | sell | 196,800 |
| Mar 23, 26 | Lazar David E. | sell | 700,000 |
| Feb 26, 26 | Jabbour Jerome D | other | 25,000 |
| Feb 26, 26 | Jabbour Jerome D | other | 0 |
| Feb 26, 26 | McMurdo Matthew Charles | other | 0 |
| Feb 11, 26 | Meckler Jeffrey A | other | 12,136 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our INDP coverage
Recent articles, reports, and earnings notes.
No research on INDP yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate INDP report →Indaptus Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
globenewswire.com · Aug 13
Abbott Cooper PLLC Announces Investigation on Behalf of Indaptus Therapeutics, Inc. Stockholders
globenewswire.com · Jun 17
Indaptus Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
globenewswire.com · May 15
Comparing Indaptus Therapeutics (NASDAQ:INDP) & Aldeyra Therapeutics (NASDAQ:ALDX)
defenseworld.net · Apr 2
Indaptus Therapeutics (INDP) Expected to Announce Quarterly Earnings on Thursday
defenseworld.net · Mar 5
Indaptus Enters Into $6 Million Securities Purchase Agreement with Investor David E. Lazar
globenewswire.com · Dec 29
Indaptus Therapeutics Chief Scientific Officer Dr. Michael Newman to Present at the Donor Selection & Cell Source Summit
globenewswire.com · Nov 17
Indaptus Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
globenewswire.com · Nov 12
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.